BR112022020359A2 - Formulações farmacêuticas - Google Patents

Formulações farmacêuticas

Info

Publication number
BR112022020359A2
BR112022020359A2 BR112022020359A BR112022020359A BR112022020359A2 BR 112022020359 A2 BR112022020359 A2 BR 112022020359A2 BR 112022020359 A BR112022020359 A BR 112022020359A BR 112022020359 A BR112022020359 A BR 112022020359A BR 112022020359 A2 BR112022020359 A2 BR 112022020359A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulations
chelating group
composition
radiohybrid
fluorine
Prior art date
Application number
BR112022020359A
Other languages
English (en)
Inventor
Bejot Romain
Haka Michael
Anzellotti Atilio
Original Assignee
Blue Earth Diagnostics Ltd
Siemens Medical Solutions Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blue Earth Diagnostics Ltd, Siemens Medical Solutions Usa Inc filed Critical Blue Earth Diagnostics Ltd
Publication of BR112022020359A2 publication Critical patent/BR112022020359A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMULAÇÕES FARMACÊUTICAS. A presente invenção refere-se a uma composição farmacêutica compreendendo um agente radiohíbrido contendo um fluoreto de silício e um grupo quelante em que o flúor é 18F ou o grupo quelante contém um metal radioativo quelado, em que a composição tem um pH de 4,0-6,0 e compreende adicionalmente: tampão citrato 0,1-200 mM; 1-100 mg / mL de etanol; e 5-10 mg / mL de cloreto de sódio.
BR112022020359A 2020-04-09 2021-04-09 Formulações farmacêuticas BR112022020359A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2005282.5A GB202005282D0 (en) 2020-04-09 2020-04-09 Pharmaceutical Formulations
PCT/GB2021/050877 WO2021205185A1 (en) 2020-04-09 2021-04-09 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
BR112022020359A2 true BR112022020359A2 (pt) 2022-12-13

Family

ID=70848115

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020359A BR112022020359A2 (pt) 2020-04-09 2021-04-09 Formulações farmacêuticas

Country Status (12)

Country Link
US (1) US20210322581A1 (pt)
EP (1) EP4132592A1 (pt)
JP (1) JP2023521402A (pt)
KR (1) KR20230024258A (pt)
CN (1) CN115484992A (pt)
AU (1) AU2021252191B2 (pt)
BR (1) BR112022020359A2 (pt)
CA (1) CA3179555A1 (pt)
GB (1) GB202005282D0 (pt)
IL (1) IL297067A (pt)
MX (1) MX2022012488A (pt)
WO (1) WO2021205185A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1356827A1 (en) * 2002-04-24 2003-10-29 Mallinckrodt Inc. Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution
ES2347535T3 (es) * 2002-11-05 2010-11-02 Ion Beam Applications S.A. Estabilizacion de composiciones acuosas de 2-fluoro-2-desoxi-d-glucosa marcada con el isotopo 18f con etanol.
CN103270004A (zh) * 2010-12-29 2013-08-28 通用电气健康护理有限公司 洗脱溶液
RU2623163C2 (ru) * 2011-12-21 2017-06-22 ДжиИ ХЕЛТКЕР ЛИМИТЕД Композиция 18f- флуцикловина в цитратных буферах
CN111132700B (zh) * 2017-07-28 2022-12-13 慕尼黑工业大学 双模放射性示踪剂与治疗剂
WO2019145293A1 (en) * 2018-01-24 2019-08-01 Ac Immune Sa Diagnostic compositions for pet imaging, a method for manufacturing the diagnostic composition and its use in diagnostics

Also Published As

Publication number Publication date
CA3179555A1 (en) 2021-10-14
EP4132592A1 (en) 2023-02-15
AU2021252191B2 (en) 2024-05-02
KR20230024258A (ko) 2023-02-20
IL297067A (en) 2022-12-01
AU2021252191A1 (en) 2022-10-27
US20210322581A1 (en) 2021-10-21
WO2021205185A1 (en) 2021-10-14
GB202005282D0 (en) 2020-05-27
CN115484992A (zh) 2022-12-16
MX2022012488A (es) 2023-01-16
JP2023521402A (ja) 2023-05-24

Similar Documents

Publication Publication Date Title
BR0317149A (pt) Métodos para uso de uma composição para bebidas
BR0316532A (pt) Composições farmacêuticas compreendendo, um composto de droga básico, respectivamente um ácido, um tensoativo e um ácido solúvel em água fisiologicamente tolerável, respectivamente, uma base
KR890015738A (ko) 이포스폰산 유도체를 기제로 하는, 경구 투역용 약학적 조성물
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
CO5700797A2 (es) Composicion de farmaco conjugado
PE20020853A1 (es) Composiciones farmaceuticas, formas de dosificacion y metodos para la administracion oral de epotilonas
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
PE20010982A1 (es) Composicion estable para dosis oral de liberacion extendida
HUP0203304A2 (hu) Prosztatarák megelőzésére szolgáló kemoterápiás módszer és készítmény
HRP20130071T1 (hr) Poboljšani testosteron u gelu i naäśin primjene
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
ES2195344T3 (es) Composicion farmaceutica que presenta una actividad antitumoral mejorada y/o efectos secundarios reducidos, que contiene un agente antitumoral y un derivado de acido hidroximico.
AR069438A1 (es) Formulaciones en solucion que contienen clorhidrato de moxifloxacina y fosfato de dexametasona para uso oftalmico u otico por via topica
BR9611815A (pt) Tablete de mascar com ação efervescente
HUP0402492A2 (hu) 5HT4 részleges agonistát tartalmazó gyógyszerkészítmények
HRP20230929T1 (hr) Stabilni pripravci semaglutida i njihova upotreba
KR950702580A (ko) 니메술라이드 염 시클로덱스트린 봉입 복합체(new nimesulide salt cyclodextrine inclusion complexes)
BR0115952A (pt) Composição de emulsão para administração terapêutica, método de administração, processo para o preparo de uma formulação contendo derivados de fosfato de agentes de transferência de elétrons
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
BR112022020359A2 (pt) Formulações farmacêuticas
KR970074763A (ko) 불소화된 비타민 d₃ 유사체
AR032362A1 (es) Formulacion topica estable de una emulsion de aceite en agua y proceso para su preparacion
HUP0302515A2 (hu) Szulfamido-tienopirimidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
BR9914834A (pt) Agente de tratamento de patobolismo ósseo, e, método para intensificar a atividade de fator inibidor de osteoclastogênese
CO5150215A1 (es) Composiciones que tienen estabilidad mejorada